We’ve detected that you are using an outdated browser. For Windows users, this site is best experienced using Google Chrome, Firefox, or Microsoft Edge


Model portrayal.
Meet Kimberly, a patient with MDD struggling with partial response on her current antidepressant
I feel slightly better since switching antidepressants, but I’m still feeling down. I worry my performance is slipping at work, and that hopeless feeling is getting worse. Some days are good, but others—I don't want to get out of bed.
—Kimberly
Not an actual patient.
- Occupation:
- Teacher, mother of two
- Age:
- 38
Meet Kimberly, a patient with MDD struggling with partial response on her current antidepressant
Current MDD Presentation
- Partial response since switching from SSRI to SNRI, despite optimal dose/duration
- Current symptoms: pessimistic thoughts, ongoing sadness, excessive worry
- Expresses reluctance to switch antidepressants
- Symptoms of anxiety
MDD, major depressive disorder; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
IS PARTIAL RESPONSE GOOD ENOUGH?
Meet Kimberly—a patient experiencing partial response on her antidepressant—and review the clinical data for REXULTI.
PATIENT WITH MDD EXPERIENCING PARTIAL
RESPONSE ON AN ANTIDEPRESSANT?
Watch the new REXULTI commercial.
Important Warning and Precaution for Neuroleptic Malignant Syndrome (NMS)
NMS is a potentially fatal symptom complex reported in association with administration of antipsychotic drugs including REXULTI. Clinical signs of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability. Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Manage NMS with immediate discontinuation of REXULTI, intensive symptomatic treatment, and monitoring.